- Home
- JRS vs TLSI Comparison
JRS vs TLSI Comparison
Compare JRS & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- TLSI
- Stock Information
- Founded
- JRS 2001
- TLSI 2010
- Country
- JRS United States
- TLSI United States
- Employees
- JRS N/A
- TLSI N/A
- Industry
- JRS Finance/Investors Services
- TLSI Medical Specialities
- Sector
- JRS Finance
- TLSI Health Care
- Exchange
- JRS Nasdaq
- TLSI Nasdaq
- Market Cap
- JRS 227.7M
- TLSI 204.0M
- IPO Year
- JRS N/A
- TLSI N/A
- Fundamental
- Price
- JRS $7.79
- TLSI $4.89
- Analyst Decision
- JRS
- TLSI Strong Buy
- Analyst Count
- JRS 0
- TLSI 5
- Target Price
- JRS N/A
- TLSI $10.90
- AVG Volume (30 Days)
- JRS 86.6K
- TLSI 153.7K
- Earning Date
- JRS 01-01-0001
- TLSI 08-13-2025
- Dividend Yield
- JRS 8.87%
- TLSI N/A
- EPS Growth
- JRS N/A
- TLSI N/A
- EPS
- JRS N/A
- TLSI N/A
- Revenue
- JRS N/A
- TLSI $32,141,000.00
- Revenue This Year
- JRS N/A
- TLSI $55.52
- Revenue Next Year
- JRS N/A
- TLSI $54.76
- P/E Ratio
- JRS N/A
- TLSI N/A
- Revenue Growth
- JRS N/A
- TLSI 46.20
- 52 Week Low
- JRS $5.95
- TLSI $3.50
- 52 Week High
- JRS $8.00
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- JRS 49.38
- TLSI 42.89
- Support Level
- JRS $7.72
- TLSI $4.85
- Resistance Level
- JRS $7.87
- TLSI $5.11
- Average True Range (ATR)
- JRS 0.12
- TLSI 0.30
- MACD
- JRS 0.01
- TLSI -0.03
- Stochastic Oscillator
- JRS 71.62
- TLSI 13.45
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.